Company Research Report: Cambridge Cognition Ltd
Company Overview
Name
Cambridge Cognition Ltd
Mission of the Company
To improve global brain health by discovering and delivering effective brain health assessments and methods for in-clinic and at-home use.
Founded
- Year: 2002
- By Whom: The company was spun out of the University of Cambridge to commercialize the CANTAB technology.
Key People
- Alex Livingstone-Learmonth - Joint Managing Director
- Rob Baker - Joint Managing Director
- Francesca Cormack - Chief Scientist
- Ricky Dolphin - Chief Technology Officer
- Maria Yancheva - CTO Winterlight
- Nick Taptiklis - Head of R&D Technology
- Liam Kaufman - VP Corporate Business Development
- Annabelle Miles - Head of Marketing
Headquarters
Cambridge, UK
Number of Employees
No information is available.
Revenue
No information is available.
About the Company
Cambridge Cognition is known for developing digital technology solutions including cognitive assessments, electronic questionnaires, and decentralised clinical trial solutions. They are trusted by leading pharmaceutical organizations and research institutions globally.
Products
Digital Cognitive Assessments
- Touchscreen Cognitive Assessments: Scientifically validated digital assessments delivering accurate cognitive performance measurement.
- Voice Analysis: Utilizes cutting-edge technology for automated verbal cognitive assessment scoring.
- Electronic Questionnaires & Scales: Digital tools for questionnaire and scale administration.
- High Frequency Testing: Short tasks for day-to-day cognitive function monitoring deployed frequently.
- Decentralised Clinical Trials: Comprehensive end-to-end clinical trial management solution.
- Ratings Quality Assurance: Enhances data quality and ensures trial success.
Key Features
- CANTAB®: The world’s most validated cognitive assessment software, recognized as the international gold standard.
- NeuroVocalix™: For voice-based cognitive assessments.
- Cognition Kit™: Wearable device solutions for high-frequency cognitive testing.
- Clinpal & eConsent: Supports study delivery, participant engagement, and data security in clinical trials.
Recent Developments
New Products and Partnerships
- 2023 CANTAB Research Grant: Focus on assessing cognitive function in breast cancer patients on chemotherapy in India.
- Partnership with the University of Essex: To gather data for strengthening CANTAB® normative offerings.
- Monument Therapeutics Spin-out: Secured £1.5m for schizophrenia clinical development.
- Collaborations with The Michael J. Fox Foundation: Using digital cognitive assessments to research Parkinson’s disease.
Latest Innovations
- Bio-Hermes-002 Project: Supported by Innovate UK grant for collecting multimodal data with cognitive assessments.
- Participation in Alzheimer’s Research: Using digital biomarkers to enhance dementia knowledge.
Other Developments
- Recognition and Validation: Supported by 3,000+ peer-reviewed publications and 250+ indications.
- Global Reach: Technologies deployed in over 100 countries and one million patients assessed.
Industry Engagement
- Scientific Advisory Board: Announced strong leadership to support ongoing research initiatives.
- Corporate Developments: Senior management team expanded to facilitate global growth.
Conclusion
Cambridge Cognition Ltd stands out as a leader in neuroscience technologies focused on brain health assessment, leveraging cutting-edge digital solutions to facilitate research and clinical trials. While revenue and employee statistics are not disclosed, the company’s partnerships and scientific validation signal its strong positioning in the market.
